Longwall Venture Partners is a specialist venture capital firm focused on backing early-stage UK companies operating in the healthcare, science, and engineering sectors.
Portfolio
5
companies
Caristo Diagnostics
Caristo Diagnostics develops AI-assisted tools for cardiac and vascular disease diagnostics.
Helio Display Materials
Helio Display Materials creates proprietary perovskite materials to improve screen performance and energy efficiency.
Kinomica
Kinomica develops proteomic data science platforms to advance precision cancer treatments.
LettUs Grow
LettUs Grow builds indoor farming technology and management software for sustainable agriculture.
Closed Loop Medicine
Closed Loop Medicine develops integrated drug and digital therapeutics to enable precision dosing.
Rebecca Todd
Investment Director
Rebecca brings venture capital experience as a partner at Longwall Venture Partners, alongside non-executive roles across several portfolio companies.
LinkedInThe financing round was led by Oxford Science Enterprises and will support market expansion in the UK, EU, and United States.
"We are thrilled that five successful institutional investors participated in the financing round which validates the vast clinical and business potential of Caristo’s innovations"
The funding round was led by Longwall Venture Partners and BGF to drive team expansion and new laboratory facilities.
"Helio is on a mission to use our world-leading perovskite science to step up the performance and efficiency of displays. This fund raising marks a change of gear for Helio, enabling us to significantly grow our capacity to design products and engage with partners in the display supply chain. I would like to thank and acknowledge our enormously supportive investors who share our vision of a bright future for perovskites in displays."
The seed round was co-led by BGF and Longwall Venture Partners with participation from seed backers including BioCity, Alderley Park Ventures, and Puffin Point.
"This marks a huge step forward for Kinomica and for KScan™, as we look to the future of cancer treatment. Our pioneering technology offers much-needed support for the development of new precision medicines and represents a new approach to drug trials and treatments that will have a huge impact on patients’ lives."
The funding round was led by Longwall Venture Partners to support research and technology scaling.
"This investment gives us a platform to really accelerate in 2020 and scale-up the delivery of our game-changing technology to farmers across the country. We’re seeing rising demand from around the world for new technologies to help farmers grow crops in ways that mitigate against the effects of climate change and ever-increasing extreme weather events."
The financing round was backed by IQ Capital, Longwall Venture Partners, Martlet, and Cambridge Angels.
"Having been in stealth mode for several years, this latest fund raising marks a significant milestone for the business and its founders. As well as securing venture capital funding from experienced investors in deep tech and life sciences, we have been able to establish corporate partnerships with international Pharma companies and the NHS, we have also hired a senior management team that represents the very best in talent across healthcare and technology."
